Emyria Ltd (EMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Emyria Ltd (EMD) has a cash flow conversion efficiency ratio of -0.316x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.67 Million ≈ $-1.18 Million USD) by net assets (AU$5.31 Million ≈ $3.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EMD company net worth for the company's overall valuation and market capitalisation.
Emyria Ltd - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Emyria Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Emyria Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Emyria Ltd ranked by their cash flow conversion efficiency. See EMD debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sikko Industries Limited
NSE:SIKKO
|
-0.100x |
|
AYS Ventures Bhd
KLSE:5021
|
0.016x |
|
Fajarbaru Builder Group Bhd
KLSE:7047
|
0.162x |
|
Adval Tech Holding AG
SW:ADVN
|
0.045x |
|
Agroton Public Ltd.
WAR:AGT
|
-0.142x |
|
Zhong An Group Limited
F:35Z
|
0.005x |
|
Hansol Pns
KO:010420
|
0.036x |
|
Averbuch Formica Center Ltd
TA:AVER
|
0.047x |
Annual Cash Flow Conversion Efficiency for Emyria Ltd (2018–2025)
The table below shows the annual cash flow conversion efficiency of Emyria Ltd from 2018 to 2025. View EMD stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.31 Million ≈ $3.75 Million |
AU$-2.70 Million ≈ $-1.91 Million |
-0.510x | +71.14% |
| 2024-06-30 | AU$2.43 Million ≈ $1.72 Million |
AU$-4.28 Million ≈ $-3.03 Million |
-1.767x | -218.22% |
| 2023-06-30 | AU$6.79 Million ≈ $4.81 Million |
AU$-3.77 Million ≈ $-2.67 Million |
-0.555x | +35.34% |
| 2022-06-30 | AU$6.32 Million ≈ $4.47 Million |
AU$-5.43 Million ≈ $-3.84 Million |
-0.859x | -56.53% |
| 2021-06-30 | AU$7.18 Million ≈ $5.08 Million |
AU$-3.94 Million ≈ $-2.79 Million |
-0.549x | +53.40% |
| 2020-06-30 | AU$3.78 Million ≈ $2.68 Million |
AU$-4.45 Million ≈ $-3.15 Million |
-1.177x | +77.33% |
| 2019-06-30 | AU$499.54K ≈ $353.46K |
AU$-2.59 Million ≈ $-1.83 Million |
-5.191x | -69937.67% |
| 2018-06-30 | AU$2.81 Million ≈ $1.99 Million |
AU$-20.82K ≈ $-14.73K |
-0.007x | -- |
About Emyria Ltd
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-… Read more